Laurus Labs concludes USFDA inspection of Visakhapatnam API facilities with 2 observations

19 Aug 2017 Evaluate

Laurus Labs has completed the US Food and Drug Administration (USFDA) inspection of its API facilities in Unit 1 and 3 in Parawada, Visakhapatnam, Andhra Pradesh, with two observations. This is a regular surveillance audit by USFDA, and the observations are procedural in nature and no data integrity issues were observed.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.


Laurus Labs Share Price

586.40 15.60 (2.73%)
27-Dec-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1391.35
Cipla 1506.35
Lupin 2227.60
Zydus Lifesciences 972.45
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.